Numbness and Tingling?

Information about how to manage or reduce the severity of BFS symptoms

Moderators: JohnV, Arron, garym

Numbness and Tingling?

Postby ImOK on November 18th, 2009, 3:31 pm

Back at some reading at PubMed - this was brought on by a visit to a dietitian who encouraged me to look into effects of l-carnitine and acetyl-l-carnitine. Because I have found these to help with my bcfs she was encouraging this and thinks I should see a physiologist. Anyone seen one of these guys? Found this interesting article about neuropathic pain and treatment using ALC - here are excerpts as I skipped the parts about diabetic neuropathy and a few other sections - the title/author is here so you can get the whole text or ask your doc about it.

Curr Neuropharmacol. 2006 July; 4(3): 233–237. PMCID: PMC2430690
Copyright © 2006 Bentham Science Publishers Ltd
L-Acetylcarnitine: A Proposed Therapeutic Agent for Painful Peripheral Neuropathies
S Chiechio,1 A Copani,2 F Nicoletti,3 and RW Gereau IV1*

Received January 31, 2006; Revised March 27, 2006; Accepted March 28, 2006.

During the past two decades, many pharmacological strategies have been investigated for the management of painful neuropathies. However, neuropathic pain still remains a clinical challenge. A combination of therapies is often required, but unfortunately in most cases adequate pain relief is not achieved. Recently, attention has been focused on the physiological and pharmacological effects of L-acetylcarnitine in neurological disorders. There are a number of reports indicating that L-acetylcarnitine can be considered as a therapeutic agent in neuropathic disorders including painful peripheral neuropathies. In this review article, we will examine the antinociceptive and the neuroprotective effects of Lacetylcarnitine as tested in clinical studies and in animal models of nerve injury.
Key Words: L-acetylcarnitine, neuropathic pain, peripheral neuropathies, antinociception

Neuropathic pain is a severe and debilitating condition which affects approximately 6 million people in the U.S. alone [2]. It accounts for a large number of patients presenting with chronic pain of nonmalignant origin. Neuropathic pain is the expression of pathological changes in the peripheral and central nervous system and may result from nerve damage caused by a variety of insults including traumatic nerve injury, metabolic diseases, viral infections, or stroke.[/color]A combination of positive and negative sensory symptoms often occurs in neuropathic pain patients. These can be summarized as follows: paresthesias (numbness or tingling), dysesthesias (electric shock phenomenon), hyperesthesia (increased sensitivity to mild painful stimuli), hyperalgesia (increased sensitivity to normally painful stimuli), hyperpathia (pain produced by subthreshold stimuli) spontaneous pain and allodynia (pain produced by normally non-painful stimuli)
Despite the different etiologies leading to neuropathic pain, increased neuronal excitability is thought to be the underlying mechanism of all forms of painful neuropathies. Therefore, the current pharmacotherapy of neuropathic pain generally involves the use of drugs that either reduce neuronal discharge or increase endogenous antinociceptive systems. Sodium-channel blockers, antiepileptic agents, opiods, tricyclic antidepressants, gabapentin etc., have been employed to treat the painful symptoms of different forms of neuropathies. However, although the main goal is to reduce pain and minimize side effects of drugs, the management of neuropathic pain should also be addressed to counteract the pathological changes that occur in many forms of neuropathies. Loss of small sensory fibers, demyelination and changes in nerve conduction velocity are common features in different forms of neuropathies. In this respect, L-acetylcarnitine is a promising compound for the treatment of painful neuropathies for its dual mechanisms, which include a significant analgesic effect after chronic administration and the ability to promote peripheral nerve regeneration and to improve vibration perception. Moreover, the apparent lack of side effects suggests that this drug might be suitable for long term treatment, an important characteristic for a chronic condition such as neuropathic pain. Thus, the data to date suggest that L-acetylcarnitine could be considered for use in neuropathic pain conditions alone or in combination with other treatments. Further large-scale controlled clinical trials are needed to assess the efficacy of L-acetylcarnitine in various neuropathic pain conditions.

Posts: 1226
Joined: June 4th, 2008, 9:19 pm

Numbness and Tingling?



Return to Symptom Management

Who is online

Users browsing this forum: Bing [Bot] and 4 guests